A composition suitable for diagnosing a musculoskeletal disease and a composition suitable for preventing or treating a musculoskeletal disease are disclosed. The composition contains zinc finger protein with KRAB and SCAN domains 8 (Zkscan8) protein, which can be effectively used as an excellent biomarker for obtaining accurate information about the occurrence and progression stages of a musculoskeletal disease, specifically a tendon disease or a ligament disease. The compositions containing Zkscan8 can be effectively used for preventing or treating a musculoskeletal disease through Zkscan8 overexpression.

The present disclosure describes a method for treating mitochondrial DNA depletion syndrome by administration of a therapeutic amount of a composition comprising a dinucleotide compound or a mixture thereof. Further described herein are compounds, compositions and methods for the treatment of TK2 deficiency.

The present disclosure describes a method for treating mitochondrial DNA depletion syndrome by administration of a therapeutic amount of a composition comprising a dinucleotide compound or a mixture thereof. Further described herein are compounds, compositions and methods for the treatment of TK2 deficiency.

The present invention provides a pharmaceutical composition for treating multiple sclerosis based on AMPK inhibitory function and zinc homeostasis controlling function that effectively treats multiple sclerosis due to its excellent neuroprotective effect without side effects.

The present invention provides a pharmaceutical composition for treating multiple sclerosis based on AMPK inhibitory function and zinc homeostasis controlling function that effectively treats multiple sclerosis due to its excellent neuroprotective effect without side effects.

The invention relates to new proline derivatives of formula (I) as cGAS inhibitors,

##STR00001##

wherein

wherein R.sup.1, R.sup.2, R.sup.3, R.sup.4, R.sup.5, R.sup.6, R.sup.7, R.sup.8, R.sup.9, R.sup.10, R.sup.11 and G are defined as in claim 1,

and prodrugs or pharmaceutically acceptable salts of these compounds

for the treatment of diseases such as systemic lupus erythematosus, systemic sclerosis (SSc), non-alcoholic steatotic hepatitis (NASH), interstitial lung disease (ILD) and idiopathic pulmonary fibrosis (IPF).

The present invention relates to an antibody-drug-conjugate. From one aspect, the invention relates to an anti-body-drug-conjugate comprising an antibody capable of binding to a Target, said antibody being conjugated to at least one drug selected from derivatives of dolastatin 10 and auristatins. The invention also comprises method of treatment and the use of said anti-body-drug-conjugate for the treatment of cancer.

The present disclosure relates to compounds that are Syk inhibitors or pharmaceutically acceptable salts or co-crystals thereof, and pharmaceutical compositions thereof, and to their use in the treatment of various disease states, including cancer and inflammatory conditions. In particular embodiments, a Syk inhibitor is a crystalline monomesylate salt of 6-(6-aminopyrazin-2-yl)-N-(4-(4-(oxetan-3-yl)piperazin-1-yl)phenyl)imidazo-[1,2-a]pyrazin-8-amine of formula 2: ##STR00001##

There is disclosed a collagen construct comprising a plurality of elongate strips, wherein each strip contains a plurality of collagen fibres that are substantially aligned along the length of the respective strips, and the strips are braided or woven together to produce a collagen construct in the form of a rope that can be used for replacing tendons or ligaments, such as cruciate ligaments. Also disclosed is a method for making or producing the collagen construct from a collagen membrane having a plurality of collagen fibres being substantially aligned parallel to each other in a common direction. The membrane is cut along cut lines that are orientated substantially parallel to that common direction, thereby to separate elongate strips from the membrane. The strips are then braided or woven together to form the collagen construct.

The invention relates to compositions including polynucleotides encoding polypeptides which have been chemically modified by replacing the uridines with 1-methyl-pseudouridine to improve one or more of the stability and/or clearance in tissues, receptor uptake and/or kinetics, cellular access by the compositions, engagement with translational machinery, mRNA half-life, translation efficiency, immune evasion, protein production capacity, secretion efficiency, accessibility to circulation, protein half-life and/or modulation of a cell's status, function, and/or activity.